Egenod T, Deslee G, Degano B
Alpes, Inserm 1300, Grenoble, France.
Service de pneumologie, hôpital universitaire Dupuytren, Limoges, France.
Rev Mal Respir. 2023 Nov-Dec;40(9-10):820-833. doi: 10.1016/j.rmr.2023.08.003. Epub 2023 Sep 6.
Chronic obstructive pulmonary disease (COPD) is associated with disabling respiratory symptoms including dyspnea, frequent exacerbations and chronic bronchitis. The currently available pharmacological and non-pharmacological therapies have limited efficacy, necessitating the development of interventional strategies, many of them endoscopic.
Endoscopic lung volume reduction has markedly increased over recent years, principally as regards the endobronchial valves currently used in routine care. Indeed, multiple randomized trials have demonstrated a significant clinical benefit in a selected population identifiable due to the absence of interlobar collateral ventilation. Other endoscopic volume reduction techniques (polymers, thermal vapor, spirals) shall require additional studies before being considered as options in routine care. Targeted lung denervation (TLD) has aroused interest as a means of reducing exacerbations in the early phases of relevant studies. Endobronchial techniques (bronchoscopic cryospray, bronchial rheoplasty) are still at a very early stage of development, which is aimed at reducing the symptoms of chronic bronchitis.
Aside from endobronchial valves, which are currently employed in routine care, all the above-mentioned endoscopic techniques require additional studies in order to determine their benefit/risk balance and to identify the population that would benefit the most.
Endoscopic treatments constitute a major avenue of research and innovation in the therapeutic management of COPD. Inclusion of patients in disease registries and clinical trials remains essential, the objective being to gauge the interest of these treatments and their future role in everyday COPD management.
慢性阻塞性肺疾病(COPD)与包括呼吸困难、频繁急性加重和慢性支气管炎在内的致残性呼吸道症状相关。目前可用的药物和非药物疗法疗效有限,因此需要开发介入策略,其中许多是内镜介入策略。
近年来,内镜下肺减容术显著增加,主要体现在目前常规治疗中使用的支气管内瓣膜方面。事实上,多项随机试验已证明,对于因不存在叶间侧支通气而可识别的特定人群,具有显著的临床益处。其他内镜下减容技术(聚合物、热蒸汽、螺旋装置)在被视为常规治疗选择之前还需要更多研究。靶向肺去神经支配术(TLD)作为在相关研究早期减少急性加重的一种手段引起了关注。支气管内技术(支气管镜冷冻喷雾、支气管成形术)仍处于非常早期的发展阶段,其目的是减轻慢性支气管炎的症状。
除了目前常规治疗中使用的支气管内瓣膜外,上述所有内镜技术都需要更多研究,以确定其效益/风险平衡,并确定最能从中受益的人群。
内镜治疗是COPD治疗管理研究和创新的主要途径。将患者纳入疾病登记和临床试验仍然至关重要,目的是评估这些治疗的价值及其在COPD日常管理中的未来作用。